ImmuPharma PLC - Asset Resilience Ratio

Latest as of December 2023: 0.00%

ImmuPharma PLC (IMM) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

GBX-1.00

≈ $-0.00 USD Cash + Short-term Investments

Total Assets

GBX2.72 Million

≈ $331.12 USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2022)

This chart shows how ImmuPharma PLC's Asset Resilience Ratio has changed over time. Check ImmuPharma PLC PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down ImmuPharma PLC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ImmuPharma PLC market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX-1.00	-0.0%
Total Liquid Assets	GBX-1.00	0.00%

Asset Resilience Insights

Limited Liquidity: ImmuPharma PLC maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

ImmuPharma PLC Industry Peers by Asset Resilience Ratio

Compare ImmuPharma PLC's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%

Annual Asset Resilience Ratio for ImmuPharma PLC (2016–2022)

The table below shows the annual Asset Resilience Ratio data for ImmuPharma PLC.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2022-12-31	-2.08%	GBX-82.56K ≈ $-10.05	GBX3.97 Million ≈ $483.61	+4.68pp
2021-12-31	-6.76%	GBX-405.49K ≈ $-49.34	GBX6.00 Million ≈ $729.76	-5.16pp
2020-12-31	-1.60%	GBX-174.49K ≈ $-21.23	GBX10.92 Million ≈ $1.33K	+12.94pp
2019-12-31	-14.53%	GBX-843.15K ≈ $-102.59	GBX5.80 Million ≈ $705.82	-37.71pp
2016-12-31	23.17%	GBX1.55 Million ≈ $189.18	GBX6.71 Million ≈ $816.39	--

pp = percentage points

About ImmuPharma PLC

LSE:IMM UK Biotechnology

Market Cap

$272.19K

GBX2.24 Billion GBX

Market Cap Rank

#31120 Global

#994 in UK

Share Price

GBX4.45

Change (1 day)

+11.25%

52-Week Range

GBX1.50 - GBX17.60

All Time High

GBX190.00